4.4 Article

Effect of resveratrol administration on ovarian morphology, determined by transvaginal ultrasound for the women with polycystic ovary syndrome (PCOS)

期刊

BRITISH JOURNAL OF NUTRITION
卷 128, 期 2, 页码 211-216

出版社

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0007114521003330

关键词

Resveratrol; Ovarian morphology; Transvaginal ultrasound; Polycystic ovary syndrome

资金

  1. Radiology Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

向作者/读者索取更多资源

Intake of resveratrol has been associated with improved ovarian morphology, as evidenced by a significantly higher rate of improvement in ovarian morphology and a more dominant follicle in women with polycystic ovary syndrome (PCOS). However, other factors like follicle count per ovary, stromal area, ovarian echogenicity, and distribution of follicles were not significantly altered.
Intake of resveratrol has been associated with improved ovarian morphology under in vitro and in the animal models; however, this finding has not been confirmed in trials. The aim of our study was, therefore, to use a placebo-controlled approach with the detailed assessment of the ovarian morphology by applying transvaginal ultrasound to examine the effectiveness of this therapeutic approach in this group of women. The mean age of all participants was 28 center dot 61 (sd 4 center dot 99) years, with the mean BMI of 28 center dot 26 (sd 5 center dot 62) kg/m(2). Resveratrol therapy, as compared with placebo, was associated with a significantly higher rate of improvement in the ovarian morphology (P = 0 center dot 02). Women who received resveratrol had a more dominant follicle than those getting placebo, with a significant reduction in the ovarian volume (P < 0 center dot 05). However, the number of follicle count per ovary (FNPO), stromal area (SA), ovarian echogenicity and distribution of follicles were not significantly altered (P > 0 center dot 05). Forty-one women with polycystic ovary syndrome (PCOS) were randomly assigned (1:1) to 3 months of daily 1000 mg resveratrol or placebo. Random assignment was done by blocked randomisation. Our primary endpoints were the change in the ovarian volume, SA and antral FNPO from the baseline to 3 months. Secondary endpoints were improvement in the distribution of follicles and ovarian echogenicity. Differences between the resveratrol and control groups were evaluated by Chi-square, Fisher's exact test and repeated-measures ANOVA. Treatment with resveratrol significantly reduced the ovarian volume and polycystic ovarian morphology, thus suggesting a disease-modifying effect in PCOS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据